SUPIMA
6.10.2020 15:02:14 CEST | Business Wire | Press release
Supima presents the 3rd annual Supima Design Lab in its very first all-digital format, which will take place on Thursday, October 8th and be streamed live on Supima’s Instagram along with Fashion Network. Once again Supima brings together a select group of up and coming and leading designers from around the world. This year’s Supima Design Lab will showcase exclusive collections designed using American-grown Supima cotton featuring designs by the winner and finalists of the 2020 Supima Design Competition, the selection of the 2020 Hyères Fashion & Photography Festival and by leading International designers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005256/en/
Created exclusively for the Supima Design Lab, each design showcases the endless possibilities of fabrics made with Supima cotton. Stemming from a commitment to design, sustainable innovation and superior quality, Supima is unwavering in its ongoing programs that create platforms for designers to express themselves despite the challenges of Covid-19.
This Year’s Digital Runway show will be presenting “Made with Supima” Exclusive Designs by;
The Winner and Finalists of the 13th Annual Supima Design Competition
Amanda Forastieri, Drexel University – This Year’s Winner
Sakura Mizutani , Fashion Institute of Design & Merchandising
Jenny Feng , Fashion Institute of Technology
Jennie Nguyen , Kent State University
Terrence Zhou , Parsons School of Design
Kyra Buenviaje , Rhode Island School of Design
Finalists of 35th International Festival of Fashion, Fashion Photography and Accessories of Hyères
Katarzyna Agnieszka (France) Andrea Grossi (Italy)
Aline Boubert (France) Marvin M’Toumo (France)
Xavier Brisoux (France) Maximilian Rittler (Belgium)
Emma Bruschi (France) Céline Shen (France)
Timour Desdemoustier (Belgium) Tom van der Borght (Belgium)
Selected Leading Designers
Thierry Colson
Lutz Huelle
Dice Kayek
Jean Paul Knott
On Aura Tout Vu
As a special addition to this year’s Supima Design Lab, there will be a round table orchestrated by Benjamin Simmenauer, Permanent Professor at Institut Français de la Mode, Fashion Expert & Brand Strategist. The round table includes a select panel of industry leaders for an in-depth discussion of the Supima Design Lab - From the Fields to the Runway. This year’s panelists include :
Jean-Pierre Blanc , Founder, International Festival of Fashion, Photography and Accessories of Hyères
Godfrey Deeny , International Editor-in-Chief, FashionNetwork
Marc Lewkowitz , President & CEO, Supima
Buxton Midyette , VP Marketing & Promotions, Supima
« We are truly honored to continue working with our SDC Partner School finalists, the selection from the Festival de Hyères and our Leading Designer group. During the pandemic, we knew it was more important than ever to stay nimble and shift the Supima Design Lab into a virtual format to support these emerging designers achieve success in the fashion industry »
Buxton Midyette, VP Marketing & Promotions, Supima
About Supima :
Supima is America’s premium cotton. Founded in 1954, the Supima brand, short for « Superior Pima », designates an elite variety of pima cotton sustainably grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color and indulgent softness.
Follow Us on Social:
Instagram: @Supima
Facebook: @Supima
Twitter: @Supima
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005256/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom